Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Juno Therapeutics, Inc. (NasdaqGS: JUNO).
On June 14, 2017, a federal court refused to dismiss a securities fraud class action against Juno and certain of its executives, which was based on the Company’s failure to disclose material information regarding the true safety and efficacy of its leading immunotherapy drug candidate, JCAR015. Following patient deaths related to the drug’s FDA trial and a suspension of the trial by the FDA, the Company eventually withdrew the drug application in March 2017. Recently, on October 24, 2017, the court ordered that the class be certified, allowing the case to move forward to trial.
A shareholder derivative lawsuit was also recently filed against the Company’s current and former executives based on alleged breach of fiduciary duty, waste of corporate assets, unjust enrichment, and other wrongful acts that caused a range of damages to the Company.
KSF’s investigation is focusing on whether Juno’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Juno shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (firstname.lastname@example.org).